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ABSTRACT 
   Actinobacillus pleuropneumoniae (APP), the etiologic agent of porcine pleuropneumonia, 
forms biofilms on both biotic and abiotic surfaces. APP biofilms confers resistance to antibiotics. 
To our knowledge, no studies have examined the role of APP biofilm in immune evasion and 
infection persistence. This study was undertaken to: (i) investigate biofilm-associated 
lipopolysaccharide modifications occurring during the switch to biofilm mode of growth; (ii) 
characterize pro-inflammatory cytokines expression in porcine pulmonary alveolar macrophages 
(PAMs) and proliferation in porcine peripheral blood mononuclear cells (PBMCs) challenged 
with planktonic or biofilm APP cells. Extracted lipid A samples from biofilm and planktonic 
cultures were analyzed by HPLC-high resolution accurate mass spectrometry. Biofilm cells 
displayed significant changes in lipid A profiles when compared to their planktonic counterparts. 
Furthermore, in vitro experiments were conducted to examine the inflammatory response of 
PAMs exposed to UV-inactivated APP grown in biofilm or in suspension. Relative mRNA 
expression of pro-inflammatory genes IL-1, IL-6, IL-8 and MCP-1 decreased in PAMs when 
exposed to biofilm cells compared to planktonic cells. Additionally, the biofilm state reduced 
PBMCs proliferation. Taken together, APP biofilm cells show a weaker ability to stimulate innate 
immune cells which could be due, in part, to lipid A structure modifications. 
KEYWORDS: Actinobacillus pleuropneumoniae, Biofilm, Cytokines, Innate immune cells, 
Lipid A, Macrophages  
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INTRODUCTION 
   Biofilms are adherent communities of bacteria attached to biological or non-biological surfaces 
and encased within a self-produced polymeric matrix that protects cells from noxious elements in 
the surrounding environment.
1,2
 Biofilm represents a serious therapeutic challenge, since bacteria 
within biofilm are usually more resistant to antibiotics and to immune clearance.
3-6
 Biofilms are 
ubiquitous and nearly all microorganisms are able to adhere to surfaces and generate biofilms. 
This includes Actinobacillus pleuropneumoniae, a Gram-negative porcine pathogen and member 
of the Pasteurellaceae family.
7
 A. pleuropneumoniae strains can form biofilms on both abiotic
7-9
 
and biotic
10
 surfaces. A. pleuropneumoniae cells within biofilms are 100 to 30,000 times more 
resistant to antibiotics than their planktonic counterparts
11
 and might play an important role in the 
persistence of bacterial infection in swine.  
   A. pleuropneumoniae is the etiologic agent of porcine pleuropneumonia, a fibrinous, 
hemorrhagic, highly contagious disease affecting pigs of all ages and leading to high economic 
losses in the swine industry.
12
 Symptoms and signs of porcine pleuropneumonia are depression, 
loss of appetite, fever, and severe breathing difficulties with some coughing.
13
 After death, it is 
common to see blood discharge out of the nasal cavity due to extensive lung tissue damage.
13
 The 
disease in its acute form is associated with high rates of morbidity and mortality.
13,14
 Lung tissues 
are damaged by the RTX toxins, ApxI, Apx II, Apx III and Apx IV.
15,16
 In addition, surface 
lipopolysaccharides (LPS) induce an inflammatory response that contributes to necrosis of 
porcine lung epithelial cell.
17-19
 Inflammatory cytokines in lung tissue may exacerbate the effect 
of A. pleuropneumoniae, and add to host-mediated tissue damage.
17,19,20
 Conversely, subclinical 
or chronic forms of the disease are asymptomatic, undetectable and less invasive.
21,22
 Chronic 
infection plays a role in persistence and transmission of several bacteria.
19,20
 Numerous studies 
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have also reported that biofilms play a role in immune evasion and bacterial survival.
23-25
 In A. 
pleuropneumoniae, most studies were performed using planktonic cells despite the important role 
played by biofilms in the pathogenesis of human and animal chronic infection.
26-29
 
   Nothing is known about how A. pleuropneumoniae biofilm interacts with immune cells, and if 
lipid A undergoes structural modifications in A. pleuropneumoniae biofilms. The purpose of this 
study was to (i) investigate modifications of lipid A occurring during the switch to the biofilm 
mode of growth and (ii) characterize the pattern of inflammatory cytokines expression in porcine 
pulmonary alveolar macrophages (PAMs) and the proliferative response of porcine peripheral 
blood mononuclear cells (PBMCs) challenged with A. pleuropneumoniae planktonic and biofilm 
cells.  
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MATERIALS AND METHODS 
Cell line and bacterial strain  
   A. pleuropneumoniae MBHPP147 (APP147) is a non-hemolytic derivative of the serotype 1 
reference strain S4074.
10
 APP147 contains deletions in both the apxIC and apxIIC genes. 
Bacterial strain was cultured in brain heart infusion (BHI) broth or agar (Oxoid Ltd, Basingstoke, 
Hampshire, England) supplemented with 15 μg/mL nicotinamide adenine dinucleotide (NAD) 
incubated at 37°C in 5% CO2. Porcine pulmonary alveolar macrophage (PAM) 3D4/21 cell line 
was purchased from the American Type Culture Collection (ATCC CRL-2843) and was 
maintained in RPMI 1640 medium (Invitrogen, Eugene, OR, USA) with 10% fetal bovine serum 
(FBS; heat inactivated) and adjusted to contain 2 mM L-glutamine (Invitrogen), 10 mM HEPES 
(Invitrogen), 1 mM sodium pyruvate, 1 mM nonessential amino acids (Invitrogen) and 0.1 
mg/mL streptomycin/100U penicillin solution (Invitrogen). Cells were cultivated in a humidified 
incubator with 5% CO2 at 37°C. 
Biofilm and planktonic cultures  
   A. pleuropneumoniae was grown in 6-well plates (Costar® 3516, Corning, Corning, NY, USA) 
as previously described.
30
 After 4 hours in culture, media containing non-attached, planktonic 
bacteria were removed (the planktonic fraction). Attached bacteria were washed twice with 
phosphate buffered-saline (PBS) to remove remaining planktonic cells. Attached cells (the 
biofilm fraction) were scraped off the plate. Both planktonic and biofilm fractions were washed 
again with PBS, centrifuged and resuspended in fresh RPMI 1640 medium. Bacterial counts 
(CFU) and optical density were used to normalize bacterial concentrations. Bacteria were killed 
using UV irradiation (254 nm, 30 min), then plated on BHI agar to verify the loss of viability. 
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Lipid A isolation 
   Lipid A molecules were extracted from both planktonic and biofilm bacteria as described by El 
Hamidi et al.
31
 Briefly, bacteria from both planktonic and biofilm fractions were lyophilized. 
Freeze-dried bacteria (10 mg) were suspended in 200 µL isobutyric acid-1M ammonium 
hydroxide mixture (5:3, v:v), and kept for 2 h at 100°C in a screw-cap test tube under agitation. 
Suspensions were cooled in ice, and then centrifuged 10 min at 2000 g. Supernatants were diluted 
with 2 volumes of water and lyophilized. The dried materials were then washed twice with 200 
µL of methanol. Finally, lipid A was extracted from pellets with 100 µL of a mixture of 
chloroform, methanol and water (3:1.5:0.25, v:v:v).  
Mass spectrometry and data processing  
   Analyses were performed using a Thermo Scientific Q-Exactive Orbitrap Mass Spectrometer 
(San Jose, CA, USA), interfaced with a Thermo Scientific UltiMate 3000 Rapid Separation 
UHPLC system, using a pneumatic assisted heated electrospray ion source (ESI). 
Chromatography was achieved using an isocratic mobile phase along with a microbore column 
Thermo Biobasic C8 100 × 1 mm, with a particle size of 5 μm. The mobile phase consisted of 
methanol and water (fortified with 0.1% of formic acid) at a ratio of 95:5. The flow rate was 
fixed at 75 µL/min and 2 µL samples were injected. Mass spectrometry was performed in 
positive ion mode and operated in scan mode at high-resolution and accurate-mass (HRAM). 
Nitrogen was used for sheath and auxiliary gases, set at 10 and 5 arbitrary units. The heated ESI 
probe was set to 4000 V and the ion transfer tube temperature was set to 300°C. The scan range 
was set to m/z 1000-2500. Data were acquired at a resolving power of 140,000 (defined as full 
width at half maximum, FWHM), resulting in a scanning rate of 700 msec/scan when using 
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automatic gain control target of 3.0 x 10
6
 and maximum ion injection time of 200 msec. The 
instrument was calibrated prior to all analyses, and mass accuracy was notably below 1 ppm 
using Thermo Pierce calibration solution and automated instrument protocol. Differential 
analyses of planktonic versus biofilm were performed using Thermo Scientific SIEVE 2.1 
software, which executes background subtraction, component detection, peak alignment and 
differential analyses. Parameters used in SIEVE were: time range 1–10 min, mass range 1000–
2500 Da, frame width 10 mDa and retention time width 2 min. SIEVE output was transferred into 
SIEVE Extractor, an Excel spreadsheet and Lipid Maps databases. SIEVE software measures p-
values using a two-tailed Student's t-test. Fold changes and p-values were used to construct a 
volcano-plot and a Venn diagram analysis. Significance was set a priori to p < 0.01 and only 2-
fold changes were considered biologically significant. 
Stimulation of porcine pulmonary alveolar macrophages 
   PAMs were prepared in 6-well plates (Costar® 3516) to a final concentration of 1 x 10
6
 viable 
cells/ml in 1.5 mL of RPMI 1640 medium. Plates were incubated at 37°C in a humidified 
incubator 5% CO2 for 24 h. Medium was removed and fresh medium containing planktonic or 
biofilm bacteria in suspension with a multiplicity of infection (MOI) of 10:1 was added to the 
wells
32
. As negative control, medium alone was added. Exposed and non-exposed cells were 
incubated for 1 to 24 h at 37°C, 5% CO2.  
Cytokine mRNA expression  
   The expression of several pro-inflammatory cytokines was determined in PAMs exposed to 
planktonic or biofilm bacteria using qRT-PCR. To begin, non-adherent PAMs were rinsed away, 
and the remaining attached macrophages were collected in Trizol reagent, and RNA was 
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extracted as described by the manufacturer (Invitrogen). Purified mRNA was resuspended in 
30µL of RNase-free water. Total RNA from samples was stored at -80°C until reverse-
transcription was done. Quantification of RNA was performed with a Nanodrop (NanoDrop 
Technologies, Inc., Wilmington, DE, USA). 1µg of total RNA was reverse-transcribed using the 
QuantiTect reverse transcription kit (Qiagen, Mississauga, ON, Canada) according to 
manufacturer’s instructions. cDNA was amplified using the SsoFast™ EvaGreen_Supermix kit 
(Bio-rad, Hercules, CA, USA). The primers used for amplification
32-34
 are presented in Table 1. 
Primer sequences were all designed from the NCBI GenBank mRNA sequences using web-based 
software primerquest from Integrated DNA technologies (www.idtdna.com/SciTools). 16-place 
Cepheid Smart Cycler
®
 System apparatus (Cepheid, Sunnyvale, CA, USA), was used for the 
cDNA amplification. Quantification of differences between groups was calculated using the 2
-
ΔΔCt
 method. β2-microglobulin was used as normalizing gene to compensate for potential 
differences in cDNA amounts. Non-infected PAM cells were used as a calibrator in the analysis. 
IL-8 quantification by ELISA 
   Levels of IL-8 in cell culture supernatants were measured by sandwich ELISA using pair-
matched antibodies from R&D Systems (Minneapolis, MN, USA), according to the 
manufacturer's recommendations. Twofold dilutions of recombinant porcine IL-8 (R&D 
Systems) were used to generate the standard curves. Sample dilutions giving optical density 
readings in the linear portion of the standard curve were used to quantify the levels of IL-8.  
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Proliferation of porcine peripheral blood mononuclear cells 
   The procedures for animal care followed the guidelines of the Canadian Council on Animal 
Care and the protocol for blood collection was approved by our Institutional Animal Care 
Committee (Protocol 13-Rech-1558). Blood was collected from 4 healthy pigs (3 to 10 weeks of 
age) into heparinized tubes, and mononuclear cells were isolated using lymphocyte separation 
medium (Wisent, St-Bruno, QC, Canada) centrifugation at 400 ×g for 30 min. The buffy coat 
containing mononuclear cells was isolated, transferred to a fresh centrifuge tube, and washed 
twice with PBS. The final cell pellet containing peripheral blood mononuclear cells (PBMC) was 
resuspended to a final level of 2 × 10
6 cells/mL in RPMI 1640 medium supplemented with 25 
mM HEPES buffer, 2 mM L-glutamine, 1 mM sodium pyruvate, 5× 10
-5
M
 
mercaptoethanol 
(Invitrogen), 0.1 mg/mL streptomycin/100U penicillin solution and 10% FBS (heat inactivated). 
Fresh isolated PBMCs cells were incubated with planktonic and biofilm cells (2 × 10
7 
cells/mL). 
As positive control, concanavalin A (5 ug/mL; Sigma-Aldrich, St-Louis, MO, USA) was used 
and fresh RPMI 1640 medium was used as negative control.  
   Cell proliferation was measured upon completion of the 48 h incubation period using a BrdU-
ELISA kit (Millipore, Billerica, MA, USA) as per manufacturer instructions. In brief, kit-
provided BrdU labeling solution (20 μL) was added to each well and the plate was incubated at 
37°C for 24 h. Thereafter, the cells were centrifuged at 300 ×g for 10 min, the labeling solution 
was removed, and the cells were fixed by addition of fixative/denaturing solution (200 μL/well) 
and incubation at room temperature for 30 min. Antibody conjugate (anti-BrdU solution, 100 
μL/well) was then added and the plate was incubated at room temperature for 1h. The cells were 
then washed twice with washing buffer (200 μL) and a peroxidase goat anti-mouse IgG HRP 
conjugate (100 μL) was added to each well for 30 min. Again, the cells were washed twice with 
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washing buffer (200 μL). Substrate solution (100 μL) was added to the wells and incubated in the 
dark at room temperature for 15 min. Then 100μL of stop solution was added and the absorbance 
in each well was measured at 450 nm in an automated plate reader (Powerwave, BioTek 
Instruments, Winooski, VT, USA). Blanks (100 μL culture medium alone) and control wells were 
included in each experiment. 
Statistical analysis 
   qRT-PCR, ELISA and PBMCs proliferation assays data were analyzed statistically using 
GraphPad Prism software (version 4.03, GraphPad Software Inc., San Diego, CA) by application 
of Wilcoxon-Mann-Whitney test or one-way ANOVA with Bartlett’s test. p < 0.05 or < 0.01 
were considered reflecting statistically significant differences.   
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RESULTS  
Lipid A structure analysis 
   Lipid A molecules were extracted following a validated protocol
31
 and their relative abundance 
in A. pleuropneumoniae planktonic and biofilm cells were analyzed using mass spectrometry. For 
both planktonic and biofilm cells, a total of 228 distinct molecular entities were observed and 
compared. Analyses were performed using an untargeted HPLC-HRAM MS lipidomic workflow. 
After data acquisition, the results were processed using bioinformatics software SIEVE 2.1 to 
perform retention time alignment and identify specific ions (i.e m/z) that differed between 
planktonic and biofilm cell groups. The m/z values for peaks of interest were searched in public 
metabolite/lipid databases (i.e. METLIN, mzCloud and Lipid MAPS) to obtain putative 
identifications without success. This is not surprising since the lipid A molecular structure and 
associated molecules for A. pleuropneumoniae remain unknown and not available in public 
databases. Following peak alignment and identification from biofilm lipid A (n = 3) and 
planktonic lipid A (n = 3), relative ion intensities and m/z values were used to study the molecular 
abundance distribution and modifications between the two cell states. Extracted data were 
represented using volcano plot with a p value = 0.01 (CI of 99%) and a two-fold change cut off 
were assumed to be biologically significant. Figure 1(a) illustrates the significant variations in 
lipid A abundance and molecular structures between A. pleuropneumoniae planktonic and 
biofilm cells with representative chromatograms shown in Figure 1(b).  
   Following an exhaustive analysis, a total of 23 lipid A structures in the planktonic fraction and 
17 in the biofilm fraction were found to be significantly different (Figure 2(a)). Inspection of the 
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detected peaks (m/z) revealed an interesting shift of the lipid A towards higher molecular weight 
in biofilm cells, as shown in Figure 2(b).  
Activation of Macrophages  
   Relative mRNA expression of pro-inflammatory cytokine genes (IL-1, IL-6, IL-8 and MCP-1) 
was measured in PAM cells following exposition to either inactivated A. pleuropneumoniae 
biofilm or planktonic cells. The expression of all tested cytokines mRNA was up-regulated when 
PAMs were exposed to A. pleuropneumoniae cells compared to unexposed control cells. qRT-
PCR data showed an early expression of all cytokines tested when exposed to planktonic cells 
(Figure 3). A peak value is reached at 1 h post-stimulation and declined shortly except for IL-8, 
which demonstrated a particularly high and sustained expression compared with the other 
cytokines.  Two other peaks at 8h and 24h post-stimulation for the MCP-1, and one peak for the 
IL-1 at 24h post-stimulation were observed. These peaks could be the result of an autoactivation 
process caused by the increase of cytokines in the culture media. 
   Interestingly, exposition of macrophages to A. pleuropneumoniae  biofilm cells appeared to 
induce significantly lower expression of pro-inflammatory cytokines and chemokines in general 
compared to macrophages exposed to planktonic cells (P<0.05) (Figure 3).  
   The level of cytokine IL-8 in the supernatant of PAM cells following exposition to either A. 
pleuropneumoniae biofilm or planktonic cells was also measured by ELISA at 1h, 2h, 4h and 8h 
(Figure 4). Our results demonstrated that the amount of IL-8 tends to increase with time. As 
expected, levels of IL-8 detected at 4h and 8h post-stimulation with biofilm cells were 
significantly lower compared to levels obtained with planktonic cells (P<0.05), confirming 
mRNA results.  
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Porcine peripheral blood mononuclear cells proliferation 
   Since A. pleuropneumoniae biofilm induces less activation of PAMs, we hypothesized that 
biofilms cells could also modulate the proliferative response of PBMCs. PBMCs were exposed to 
both biofilm and planktonic cells, and the proliferation was evaluated and compared to 
unexposed cells (negative controls) (Figure 5). As expected, a significantly higher proliferation 
was observed when immune cells were exposed to concanavalin A or A. pleuropneumoniae cells 
(planktonic and biofilm) compared to unexposed cells control (P<0.05). The proliferative 
response of PBMCs exposed to planktonic and biofilm cells was then evaluated. Biofilm cells 
induced a lower response compared to their planktonic counterparts (P<0.05) (Figure 5).  
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DISCUSSION 
   Lipopolysaccharide (LPS) has been implicated as one of the major virulence factors in A. 
pleuropneumoniae
18,36-38
 and other Gram-negative bacteria.
39,40
 LPS has several functions. First 
of all, it protects bacteria by establishing a permeability barrier.
40-42
 The biological activity of 
LPS stems from its hydrophobic anchor, lipid A,
39
 which stimulates the Toll-like receptor 4 
(TLR4), found on the surface of monocytes, macrophages and neutrophils.
43-45
 Lipid A will first 
bind the co-receptor MD-2, before interacting with the TLR4 receptor.
43,44
 The formed complex 
TLR-4/MD-2/LPS subsequently activates transcription factor NF-kB and pro-inflammatory 
cytokines IL-1, IL-6 and IL-8.
45,46
 Several structural modifications in lipid A, such as the loss of 
phosphate groups and variation in length and number of the fatty acyl chains, have an important 
role in TLR4 recognition and response.
40,45,47-50
 Variations in lipid A structure provide bacteria 
fitness advantages to colonize surfaces, evade the immune system and persist during 
infections.
49,51,52
 Some of these variations are associated with chronic infection
51,53
 and biofilm 
formation.
47
  
   Biofilm bacteria are encased within a polymeric matrix that contains among other things, 
polysaccharides, extracellular DNA, proteins and lipids.
54-56
 They are frequently associated with 
chronic disease
25,26,57
 and represent a serious therapeutic challenge, since bacteria within biofilm 
exhibit enhanced antibiotic tolerance and are more resistant to clearance by the immune 
system.
3,11,24,57
 We recently demonstrated that LPS has an important role in biofilm formation in 
A. pleuropneumoniae, and that a biofilm matrix exopolysaccharide, poly-N-acetyl-D-
glucosamine, can interact specifically with LPS
30
. However, the impact on host cells of LPS and 
particularly lipid A in biofilms remains to be determined.    
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   In this study, using an HPLC-HRAM MS untargeted lipidomic based approach, we 
demonstrated that lipid A molecular structure seems to be influenced by the bacterial mode of 
growth (sessile or planktonic). Planktonic and biofilm cells differed significantly in lipid A 
structure and quantity, with larger lipid A molecular entities observed in biofilm cells. This 
constitutes an additional manner biofilm cells differ phenotypically from their free-floating 
counterparts.
58-60
 However, further analyses will be required to determine molecular identity (i.e. 
extensive purification and 
1
H / 
13
C NMR).   
   Lipid A contributes to cell rigidity by increasing cell wall strength.
61,62
 During biofilm 
formation, embedded bacteria may exert pressure on their neighbors,
62
 and the increased 
molecular interactions could favor reactions leading to modified lipid A structures and cell 
surface remodeling.   
   Several studies have demonstrated that biofilms can undergo LPS structural modifications that 
modulate the immune response.
47,48,51
 Recently, Chalabaev and colleagues described an 
interesting biofilm associated-phenotype linked to lipid A structure.
47
 They found that among 
several Gram-negative bacteria, including Escherichia coli and Pseudomonas aeruginosa, lipid A 
can undergo palmitoylation, and these changes were found to be more abundant in biofilm than in 
planktonic cells.
47
 Lipid A structural modifications, including addition of arabinose and palmitate 
were also observed in P. aeruginosa strains isolated from patients with cystic fibrosis, a chronic 
lung infection wherein biofilms have a preponderant role.
51,53
 These modifications were 
associated with resistance to host innate defenses and persistence.
53
 In biofilms, lipid A 
modification may confer a fitness advantage by enabling bacteria to escape and survive host 
defense systems, by increasing steric hindrance, and by promoting chronic infection. 
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   Cytokines like IL-1, IL-6, IL-8 and MCP-1 play important roles in mediating inflammatory 
response to pathogens. Pro-inflammatory IL-8 and MCP-1 trigger neutrophils migration to the 
site of the infection. One of our objectives was to see how planktonic and biofilm A. 
pleuropneumoniae cells interact with immune cells. Our data indicate that biofilm cells trigger a 
different innate immune response than do planktonic cells. Previous studies showed that A. 
pleuropneumoniae infections were followed by increased TNF, IL-1 and IL-8 mRNA expression. 
These cytokines were detected at the periphery of the lung lesion.
17,63
 Increased inflammatory 
cytokine levels were also seen in lung lesions from acute porcine pleuropneumonia.
17,63
  
   Using IL-10 gene therapy, Morrison et al. demonstrated that this anti-inflammatory cytokine 
can diminish levels of pro-inflammatory cytokines, IL-1 and TNFα, and consequently reduce 
lung damage and severity in pleuropneumonia.
20
 In this study, we observed that levels of pro-
inflammatory cytokines were significantly lower in PAMs exposed to biofilm cells compared to 
those exposed to planktonic cells. Furthermore, porcine PBMCs exhibited a lower proliferative 
response when exposed to biofilm compared to planktonic cells. Overall our data suggest that the 
biofilm mode of growth mitigates the innate immune response to this pathogen.   
   The role of biofilm in chronic disease and low-level inflammation response is increasingly 
recognized. Many studies support this hypothesis.
64,65
 Daw et al. showed that macrophages 
infected with of Enterococcus faecalis biofilm cells secreted lower pro-inflammatory cytokine 
levels compared to planktonic cells.
66
 Similarly, macrophages infected with Legionella 
pneumophila biofilm exhibited significantly lower levels of pro-inflammatory cytokine IL-1β, 
compared to those infected with planktonic bacteria.
67
 In this way, biofilm-derived L. 
pneumophila avoids major inflammatory responses and recruitment of inflammatory cells.
67
    
Similarly, Thurlow et al. demonstrated that Staphylococcus aureus biofilm evades TLR 
recognition and alters the immune response to infection.
68
 Indeed, several inflammatory signals 
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including MCP-1, TNF-α, and IL-1β were significantly attenuated in S. aureus biofilm-infected 
tissues compared to the wound healing response elicited by insertion of sterile catheter.
68
 
   Less lung lesions and low inflammation and are often associated with the chronic form of 
pleuropneumonia
17,20,63
 suggesting the involvement of biofilm. A. pleuropneumoniae growing in 
biofilm may overcome host defenses by modifying its lipid A structure, which enables a lower 
immune reactivity. However, lipid A structural modifications may not be the sole cause of the 
immune dysfunction observed here and other bacterial surface components may also be 
implicated. Further studies will be needed to demonstrate the direct impact of these biofilm 
associated-lipid A structural modifications in the altered immune response. 
   The lipid A structure in A. pleuropneumoniae has yet to be elucidated. However, fatty acids in 
the lipid A of A. pleuropneumoniae serotype 1 were identified, and it was shown that lipid A 
contains different proportions of n-dodecanoic acid (0.6%), n-tetradecanoic acid (12.9%), 3-
hydroxytetradecanoic acid (64.3%), n-hexadecanoic acid (3.2%), and n-octadecanoic acid 
(0.6%).
69
 Knowing lipid A structure and the fatty acids arrangement in A. pleuropneumoniae 
would help to identify the modifications occurring in lipid A during the switch from planktonic to 
biofilm form and identify their impact on immune response. 
   This study demonstrates that the A. pleuropneumoniae biofilm mode of growth has an impact 
on lipid A structure and mitigates the innate immune response. Further investigation must focus 
on these lipid A modifications associated with lower immune cells stimulation.   
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Table 1. Primers used for quantitative real-time reverse-transcriptase (RT)-PCR. 
Primer Sequence Size (bp) References 
β2m B2m_Fw CGTGGCCTTGGTCCTGCTCG 
B2m_Rev TCCGTTTTCCGCTGGGTGGC 
103 (33) 
IL-1α IL1a_Fw TGAAGATGGCCAAAGTCCCTGACCT 
IL1a_Rev ATCCATGCCGTCCCCAGGAAGTG 
152 (34) 
IL-6 IL6_Fw ACTCCCTCTCCACAAGCGCCTT 
IL6_Rev TGGCATCTTCTTCCAGGCGTCCC 
105 (34) 
IL-8 IL8_Fw TGTGAGGCTGCAGTTCTGGCAAG 
IL8_Rev GGGTGGAAAGGTGTGGAATGCGT 
80 (34) 
MCP-1 MCP-1_Fw CAGGTCCTTGCCCAGCCAGATG 
MCP-1_Rev CACAGATCTCCTTGCCCGCGA 
143 (35) 
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Figure 1. (a) Volcano plot of distribution of A. pleuropneumoniae lipid A structures isolated 
from biofilm cells (n = 3) or planktonic cells (n = 3).The volcano plot displays the relationship 
between fold-change and significance between the two groups, using a scatter plot view. The y-
axis is the negative log10 of P values (a higher value indicates greater significance) and the x-
axis is log2 fold change or the difference in abundance between two experimental groups. The 
dashed red-line shows where p = 0.01 with points above the line having P < 0.01 and points 
below the line having P > 0.01. (b) Chromatograms of structures indicate by black arrows in the 
volcano plot.   
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Figure 2. Actinobacillus pleuropneumoniae biofilm and planktonic lipid A structures 
distribution. (a) Venn diagram showing the differential abundance of lipid A structures between 
planktonic and biofilm cells with two fold change or higher and P value > 0.01. (b) Distribution 
of small (1000-2000 Da) and large (2000-4500 Da) molecular weight (MW) lipid A structures in 
biofilm and planktonic cells.  
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Figure 3. Cytokine expression in porcine pulmonary alveolar macrophages exposed to biofilm 
(BIOF) or planktonic (PLK) cells of A. pleuropneumoniae (MOI 10:1) for different time periods 
(1h to 24h). Fold changes in mRNA expression of (a) IL-1, (b) IL-6, (c) IL-8 and (d) MCP-1 
relative to the uninfected control are presented. The means ± SD from 3 independent experiments 
are shown. Statistical analyses were performed using 2
-ΔΔCt
 values and all results with (*) or (**) 
were statistically significant (P <0.05 or P <0.01 respectively).   
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Figure 4. IL-8 production by PAMs in response to stimulation by planktonic (PLK) and biofilm 
(BIOF) cells (MOI 10:1) for different time periods (1h to 8h). Data are expressed as mean ± SD 
(in pg/ml) from at least three independent experiments and results with (*) were statistically 
significant (P <0.05).  
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Figure 5. Proliferation of porcine peripheral blood monocytes exposed to biofilm and planktonic 
cells of A. pleuropneumoniae (2 × 10
7 
cells/mL). Proliferation rate in PBMCs stimulated with 
concanavalin A (ConA), planktonic (PLK) and biofilm cells (BIOF) of A. pleuropneumoniae was 
evaluated using a BrdU-ELISA assay. The means ± SD from 3 independent experiments are 
shown. (*) or (**), results were statistically significant (P < 0.05).  
 
 
 
 
 
